NCT03119974View on ClinicalTrials.gov

Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP

PHASE4CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

August 26, 2020

Study Completion Date

February 16, 2021

Conditions
Persistent or Chronic ITP
Interventions
DRUG

Tpo-RA discontinuation

a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (\> 2 months) complete response (platelets counts \> 100 x 109/L) period on Tpo-RA treatment.

Trial Locations (1)

94010

Henri-Mondor Hospital, Créteil

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT03119974 - Rate of Prolonged Response After Stopping Thrombopoietin-receptor Agonists Treatment in ITP | Biotech Hunter | Biotech Hunter